From our Annual Public Meeting to topic-specific convenings, the Reagan-Udall Foundation for the FDA brings stakeholders together on matters critical to regulatory science and practice. These events, often hosted at the request of FDA leadership, provide space for expert analysis and candid discussion on FDA’s priority issues. See below for upcoming events.

Past Events

Natural History Studies and Registries in the Development of Rare Disease Treatments

The Reagan-Udall Foundation for the FDA, in collaboration with FDA’s Rare Diseases Team within the Office of Rare Diseases, Pediatrics, Urologic and Reproductive Medicine; Office of New Drugs; Center for Drug Evaluation and Research and the National Institutes of Health’s Division of Rare Diseases Research Innovation within the National Center for Advancing Translational Sciences, is hosting a public workshop.

2024 Annual Public Meeting

Each year, the Reagan-Udall Foundation for the FDA conducts an annual public meeting to discuss its activities in support of the FDA.

Qualifying Biomarkers to Support Rare Disease Regulatory Pathways

Qualifying Biomarkers to Support Rare Disease Regulatory Pathways
-

Advancing Psychedelic Clinical Study Design

Advancing Psychedelic Clinical Study Design Virtual Public Meeting Day 1: January 31, 2024 | 10am-2pm (eastern)

2023 Innovations in Regulatory Science Awards

2023 Innovations in Regulatory Science Awards recognize Dr. Collins, Rep. DeGette, Rep. Upton for contributions to regulatory science & public health

Front-of-Package Nutrition Labeling

Front-of-Package Nutrition Labeling Virtual Public Meeting

Integrating Clinical Studies Into Health Care Delivery: Post-Market Evidence Generation for Medical Products

Integrating Clinical Studies Into Health Care Delivery: Post-Market Evidence Generation for Medical Products Virtual Public Meeting

Virtual Public Meeting: Strategies for Improving Public Understanding of FDA-Regulated Products

Strategies for Improving Public Understanding of FDA-Regulated Products Virtual Public Meeting

Public Meeting: Mitigating Risks from Human Xylazine Exposure

Mitigating Risks from Human Xylazine Exposure Public Meeting: In-person and Virtual 
-

Good Clinical Practice: Considerations for Trials with Pragmatic or Decentralized Features

On September 12 and 13, the Foundation, in collaboration with the U.S. Food and Drug Administration, hosted a webinar to explore Good Clinical Practice Considerations for Trials with Pragmatic or Decentralized Features.